Key facts

Invented name
Ibrance
Active Substance
Palbociclib
Therapeutic area
Oncology
Decision number
P/0005/2019
PIP number
EMEA-002146-PIP02-18
Pharmaceutical form(s)
  • Capsule (hard)
  • Age-appropriate oral dosage form
  • Tablet
Condition(s) / indication(s)
Treatment of breast malignant neoplasms
Route(s) of administration
Oral use
Contact for public enquiries

Pfizer Europe MA EEIG

Tel. +44 1304 6466 07
E-mail: pip_enquiries@pfizer.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/0005/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for palbociclib (IBRANCE) (EMEA-002146-PIP02-18)

How useful do you find this page?